EUVIMEDEUVIMED entdecken
Crossref

N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis

Giuseppe Vergaro, Vincenzo Castiglione, Alberto Aimo, Concetta Prontera, Silvia Masotti, Veronica Musetti, Martin Nicol, Alain Cohen Solal, Damien Logeart, Georgios Georgiopoulos, Vladyslav Chubuchny, Alberto Giannoni und 12 weitere

European Journal of Heart Failure · 01.03.2023 · 25 (3) · 335-346

DOI: 10.1002/ejhf.2769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 11.01.2023. Verfasst von Giuseppe Vergaro und 23 weiteren Autor:innen. Beteiligte Einrichtung: 'Health Science' Interdisciplinary Research Center, Pisa, Italy. Hauptthemen laut MEDLINE: Heart Failure, Amyloidosis. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cardiac amyloidosis (CA) is associated with an elevation of natriuretic peptides and troponins, predicting outcome. Nevertheless, the diagnostic yield of these biomarkers has not been extensively investigated. This study aimed to evaluate the diagnostic performance for CA of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT). Methods and results Patients with suspected CA (n = 1149) underwent a diagnostic work-up in three centres in Italy, France (n = 343, derivation cohort), and United Kingdom (n = 806, validation cohort). Biomarker values with either 100% sensitivity or ≥95% specificity were selected as rule-out/rule-in cut-offs, respectively. In the derivation cohort, 227 patients (66%) had CA, and presented with higher NT-proBNP and hs-TnT. NT-proBNP 180 ng/L and hs-TnT 14 ng/L were selected as rule-out cut-offs, and hs-TnT 86 ng/L as rule-in cut-off. NT-proBNP <180 ng/L or hs-TnT <14 ng/L were found in 7% of patients, and ruled out CA without false negatives. In the validation cohort, 20% of patients (2% false negatives) had NT-proBNP <180 ng/L or hs-TnT <14 ng/L, and 10% showed both biomarkers below cut-offs (0.5% false negatives). These cut-offs refined CA prediction when added to echocardiographic scores in patients with a haematologic disease or an increased wall thickness. In the validation cohort, the 86 ng/L hs-TnT cut-off ruled in 20% of patients (2% false positives). NT-proBNP and hs-TnT cut-offs retained their rule-out and rule-in performance also in cohorts with CA prevalence of 20%, 10%, 5% and 1% derived from the original cohort through bootstrap analysis.

Conclusions

Cardiac biomarkers can refine the diagnostic algorithm in patients with suspected CA. NT-proBNP <180 ng/L and hs-TnT <14 ng/L reliably exclude the diagnosis, both in the overall population and subgroups referred for either AL-CA or cardiac (pseudo)hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloidosisHumansTroponin TNatriuretic Peptide, BrainPeptide FragmentsBiomarkersPrognosis

Stichwörter der Autor:innen

BiomarkersCardiac amyloidosisDiagnosisNT-proBNPTroponin

Substanzen

Troponin Tpro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainPeptide FragmentsBiomarkers

Autor:innen und Institutionen

  • 'Health Science' Interdisciplinary Research Center, Pisa, Italy.
  • Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
  • Cardiology Department, Hôpital Lariboisière, Paris, France.
  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Hematology Department, University of Pisa, Pisa, Italy.

Zitieren

APA

Vergaro, G., Castiglione, V., Aimo, A., Prontera, C., Masotti, S., Musetti, V., Nicol, M., Cohen Solal, A., Logeart, D., Georgiopoulos, G., Chubuchny, V., Giannoni, A., Clerico, A., Buda, G., Patel, K. N., Razvi, Y., Patel, R., Wechalekar, A., Lachmann, H., …, & Fontana, M. (2023). N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. European Journal of Heart Failure, 25(3), 335-346. https://doi.org/10.1002/ejhf.2769

Vancouver

Vergaro G, Castiglione V, Aimo A, Prontera C, Masotti S, Musetti V, et al. N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. European Journal of Heart Failure. 2023;25(3):335-346. doi:10.1002/ejhf.2769

BibTeX
@article{Vergaro2023,
  author = {Vergaro, Giuseppe and Castiglione, Vincenzo and Aimo, Alberto and Prontera, Concetta and Masotti, Silvia and Musetti, Veronica and Nicol, Martin and Cohen Solal, Alain and Logeart, Damien and Georgiopoulos, Georgios and Chubuchny, Vladyslav and Giannoni, Alberto and Clerico, Aldo and Buda, Gabriele and Patel, Kiara N and Razvi, Yousuf and Patel, Rishi and Wechalekar, Ashutosh and Lachmann, Helen and Hawkins, Philip N and Passino, Claudio and Gillmore, Julian and Emdin, Michele and Fontana, Marianna},
  title = {N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis},
  journal = {European Journal of Heart Failure},
  year = {2023},
  volume = {25},
  number = {3},
  pages = {335--346},
  doi = {10.1002/ejhf.2769}
}
Kostenlos starten →